Weight & metabolism

Pramlintide

Peptilex evidence grade ABCDEUpdated 19 Oct 2026 How grades work

Type: Analogues of the pancreatic hormone amylin
Main use or focus: Diabetes (with insulin)
Also known as: Symlin

Research at a glance

Publications by typePubMed, all years

All papers445

Human studies352

Animal studies only28

Randomized trials64

Meta-analyses & systematic reviews5

Source: PubMed and ClinicalTrials.gov via the Peptilex study database

Registered trials by phaseClinicalTrials.gov · name in study title

ongoing / startingcompleted / other

Phase 15

Phase 214

Phase 36

Phase 49

Other12

Source: PubMed and ClinicalTrials.gov via the Peptilex study database

Trial starts per yearClinicalTrials.gov · by start date (planned starts included)

2016

12018

12020

12022

12024

2026

Source: PubMed and ClinicalTrials.gov via the Peptilex study database

Go deeper

Full profile in the book

What it is, how it acts, the key studies, risks and open questions.

Peptilex – The Peptide Encyclopedia

34 peptides – from semaglutide to BPC-157 – in one book
An evidence grade (A–E) and the key studies for every peptide
Where each one stands in 2026 – US, EU and Switzerland

View on Amazon

Formats: Kindle · Paperback · Hardcover

Amazon store: amazon.com · Change store

Coming soonPeptilex – The Honest GLP-1 HandbookSemaglutide, tirzepatide and the new pills, explained for adults over 50.

Registered trials

ClinicalTrials.gov · name in study title · ongoing first

Study	Phase	Status	Participants	Start
A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes NCT00240253AstraZeneca	Phase 4	Completed	200	Oct 2005
A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes NCT00467649AstraZeneca	Phase 4	Completed	112	May 2007
Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia NCT01269047Albert Einstein College of Medicine	Phase 4	Completed	37	Aug 2009
Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia NCT00690235University of Texas Southwestern Medical Center	Phase 4	Completed	33	Nov 2007
Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery NCT01841359Joslin Diabetes Center	Phase 4	Completed	22	Feb 2010
The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes NCT00950677Baylor College of Medicine	Phase 4	Completed	16	Jul 2009
Continuous Subcutaneous Infusion of Pramlintide and Insulin NCT00291772Baylor College of Medicine	Phase 4	Completed	13	Jan 2006
A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes NCT00502138University Diabetes & Endocrine Consultants	Phase 4	Completed	12	Jul 2007
Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus NCT00108004AstraZeneca	Phase 3	Completed	400	Apr 2003
Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus NCT00107107AstraZeneca	Phase 3	Completed	190	Nov 2002

Show 15 moreShow fewer

Study	Phase	Status	Participants	Start
The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes NCT00206297Baylor College of Medicine	Phase 3	Completed	20	Oct 2003
Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects NCT00673387AstraZeneca	Phase 2	Completed	636	Apr 2008
A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects NCT00112021AstraZeneca	Phase 2	Completed	400	May 2005
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects NCT00402077AstraZeneca	Phase 2	Completed	258	Nov 2006
A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects NCT00189514AstraZeneca	Phase 2	Completed	210	Sep 2005
Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects NCT00444561AstraZeneca	Phase 2	Completed	184	Aug 2004
A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects NCT00392925AstraZeneca	Phase 2	Completed	177	Oct 2006
Evaluation of the Bioavailability of Pramlintide NCT00042471AstraZeneca	Phase 2	Completed	75	Jun 2002
Evaluation of the Effect of Pramlintide on Satiety and Food Intake NCT00042601AstraZeneca	Phase 2	Completed	51	Jul 2002
Effect of Basal-Bolus Closed-Loop Co-Administration of Insulin and Pramlintide on Improving the Glycemic Control in Type 1 Diabetes NCT02814123McGill University	Phase 2	Completed	28	Jan 2017
Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide NCT00044707AstraZeneca	Phase 2	Completed	24	Aug 2002
Insulin-plus-pramlintide Closed-loop Strategy to Regulate Glucose Levels Without Carbohydrate Counting NCT03800875McGill University	Phase 2	Completed	24	Feb 2019
A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus NCT00313183AstraZeneca	Phase 2	Completed	12	Apr 2006
A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus NCT03916640Adocia	Phase 1	Completed	24	Jan 2019
A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus NCT03512236Adocia	Phase 1	Completed	24	Apr 2018

Showing 25 of 46 matching registered studies. See all on ClinicalTrials.gov.

Latest key papers

PubMed · newest first

2025
A Pilot Outpatient Assessment of a Fully Closed-Loop Insulin and Pramlintide System
Human RCTOdabassian M et al. · Journal of Diabetes Science and TechnologyPMID 41174925
2024
ADO09, a co-formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes
Human RCTAndersen G et al. · Diabetes, Obesity & MetabolismPMID 39109464
2024
Simple meal announcements and pramlintide delivery versus carbohydrate counting in type 1 diabetes with automated fast-acting insulin aspart delivery: a randomised crossover trial in Montreal, Canada
Human RCTCohen E et al. · The Lancet. Digital HealthPMID 38906614
2023
A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes
Human RCTAndersen G et al. · Diabetes, Obesity & MetabolismPMID 36633505
2021
Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients
Human RCTGhanizada H et al. · Annals of NeurologyPMID 33772845
2021
Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis
Meta-analysisAvgerinos I et al. · Diabetes, Obesity & MetabolismPMID 33300282
2020
A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial
Human RCTHaidar A et al. · Diabetes CarePMID 31974099
2015
Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis
Meta-analysisDomecq JP et al. · J Clin Endocrinol MetabPMID 25590213

Related peptides

ASemaglutide ATirzepatide BRetatrutide BCagriSema (cagrilintide)ALiraglutide ASetmelanotide CAOD-9604